Sunrise Parkinson's Disease Clinical Study
Advancing Parkinson's research begins with you.
The trial drug, NE3107, also known as Bezisterim, is a new molecule with a unique mechanism of action that is believed to have the potential to interrupt both inflammation and insulin resistance in the brain, two factors that are fundamental to both the clinical symptoms and progression of Parkinson’s disease (PD). In animal studies, the trial drug showed that the reduction of neuroinflammation led to improved movement, a decrease in the levodopa side effects, as well as a decrease in the loss of brain cells, which means it has the potential to slow disease progression. This clinical trial will test whether NE3107’s benefits for PD seen in animal studies translate to benefits in Parkinson’s patients that have not yet started to receive treatment or have only taken a medicine called a monoamine oxidase B inhibitor to help them move.
Find out how you or a loved one can make a difference by participating in a clinical trial today.
You may be eligible if you:
- Are 45-80 years of age
- Have been diagnosed with Parkinson’s Disease not more than 18 months prior to screening and not more than 36 months has passed since first motor symptom prior to screening.
- Have not been prescribed levodopa (Sinemet or Rytary) or dopamine receptor agonists (Pramipexole [Mirapex®], Ropinirole, Apomorphine, Rotigotine), but believe that you now need or will soon need medicine to help you with your Parkinson’s symptoms.
- Are in generally otherwise good health
Additional criteria apply
